Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted prote…
FTSE Mixed as UK Lags Global Rally
London stocks opened mixed on Monday, with the FTSE 100 edging up 0.1% to 9,651.66 as the UK market lag…
Throwback Series: Managing Bilateral Diabetic Macular Edema
David Eichenbaum, MD, FASRS, recalls a notable case from early in his practice…
Compulsory Voting: A Remedy or Ruse for Democracy?
The debate over compulsory voting revolves around a trade-off between participation and…
Microsoft Facing Lawsuit Over Unfair Software Pricing
Microsoft is being sued by the Australian Competition & Consumer Commission (ACCC) f…
From Pills to People: The Rise of Social Prescribing
Karen Mak brings you a bumper edition blog on social prescribing, finding that rates …
SAHPRA Approves Groundbreaking HIV Prevention Injection
The South African Health Products Regulatory Authority (SAHPRA) has approved a new…
Hemab Secures $157M to Address 'Underserved' Blood Diseases
Hemab, a startup with medicines in testing and development, aims to build the …
Teachers Licensing Initiative to Uphold Education Standards
The Botswana Teaching Professionals Councils (BOTEPCO) has launched a teacher …
Nokia, Ericsson and Fraunhofer Partnership for NextGen Video Compression
Nokia, Ericsson, and Germany's Fraunhofer Heinrich Hertz Institut…